lemuteporfin
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2005 (NCT00116571)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
C=CC1=C(C)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5CCC(=O)OCCC)C(CCC(=O)OCCO)=C4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC- Mol. weight
- 790.91 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107756 ↗
Also known as
- lemuteporfin
- lemuteporfin
- lemuteporfin
- lemuteporfin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01490736 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2011 | Dermira, Inc., Innovaderm |
| NCT00116571 | Phase 2 | May 1, 2005 | Novelion Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dermira, Inc. | For profit | 1 | 1 | 1 | 2011 |
| Innovaderm | For profit | 1 | 0 | 1 | 2011 |
| Novelion Therapeutics | For profit | 1 | 1 | 1 | 2005 |
3 organizations
Page 1 / 1